Cargando…
Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
BACKGROUND: Treatment of advanced melanoma has been improved with the advent of the BRAF inhibitors. However, a limitation to such treatment is the occurrence of resistance. Several mechanisms have been identified to be responsible for the development of resistance, either MEK-dependent or MEK-indep...
Autores principales: | Fattore, Luigi, Marra, Emanuele, Pisanu, Maria Elena, Noto, Alessia, de Vitis, Claudia, Belleudi, Francesca, Aurisicchio, Luigi, Mancini, Rita, Torrisi, Maria Rosaria, Ascierto, Paolo Antonio, Ciliberto, Gennaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729364/ https://www.ncbi.nlm.nih.gov/pubmed/23890105 http://dx.doi.org/10.1186/1479-5876-11-180 |
Ejemplares similares
-
Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition
por: Fattore, Luigi, et al.
Publicado: (2014) -
ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
por: Fattore, Luigi, et al.
Publicado: (2015) -
Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma
por: Fattore, Luigi, et al.
Publicado: (2015) -
The promise of anti-ErbB3 monoclonals as new cancer therapeutics
por: Aurisicchio, Luigi, et al.
Publicado: (2012) -
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression
por: Ciardiello, Chiara, et al.
Publicado: (2016)